Haemonetics Corporation
HAEHealthcareNASDAQMedical Devices
Scan Results
Daily timeframePart of the healthcare sector, Haemonetics Corporation (HAE) is listed under Medical Devices. At a $3.54B market cap, Haemonetics Corporation ranks as a mid-cap company within healthcare. The company operates through Plasma, Blood Center, and Hospital segments.
Market Cap
$3.54B
Beta
0.52
P/E (TTM)
38.35
P/E (Fwd)
13.84
EPS (TTM)
$2.03
EPS (Fwd)
$5.63
ROE
12.0%
ROA
6.5%
Cash
$246.3M
Total Debt
$1.27B
Free CF
$298.1M
52W Change
7.3%
Annual Financials
Cash vs Debt
Haemonetics Corporation carries $1.27B in total debt against $246.3M in cash reserves — debt is roughly 5.2x the cash position. Managing this leverage effectively will be important for long-term financial stability. Annual free cash flow of $298.1M supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. Return on equity stands at 12.0%, which is decent for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. An ROA of 6.5% suggests reasonable efficiency in deploying the company's asset base. Revenue has been uneven over recent years, ranging from $1.17B to $1.33B.
The relatively low beta of 0.52 suggests HAE is a less volatile holding compared to the broader index. Haemonetics Corporation carries a heavier debt load relative to its cash position, which introduces financial risk that investors should weigh. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Haemonetics Corporation's trajectory.